Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus + Dalotuzumab vs Exemestane in ER+ Breast Cancer
NCT01234857Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2010
- Primary completion
- Oct 2013
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
Phase 2, randomised, open-label trial of ridaforolimus and dalotuzumab in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Progression Free Survival. Started Sep 2010; status: completed.
02
Drugs
ridaforolimusdalotuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01234857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234857.